As the landscape of hematopoietic stem cell transplantation (HSCT) continues to evolve, umbilical cord blood transplantation (CBT) maintains a critical position in the treatment of hematologic malignancies due to its unique immunological advantages. However, delayed engraftment and high non-relapse mortality (NRM) were once significant bottlenecks limiting its clinical utility. At a recent academic symposium, Professor Annalisa Ruggeri—Chair of the Cell Therapy & Immunobiology Working Party (CTIWP) of the European Society for Blood and Marrow Transplantation (EBMT) and Scientific Chair of Eurocord—delivered a profound presentation on "Regenerative Cord Blood Transplantation." Professor Ruggeri provided an in-depth analysis of the latest advancements, ranging from the optimization of donor selection and conditioning regimens to breakthrough ex vivo expansion technologies such as UM171. Her insights highlighted how technical innovations are overcoming traditional limitations of CBT to deliver superior survival outcomes for high-risk patients. 01 Immunobiological Characteristics and the Current State of CBT
Professor Annalisa Ruggeri first emphasized the unique biological advantages of umbilical cord blood (UCB) as a source for hematopoietic stem cells. UCB cells are characterized by their high degree of naivety, longer telomeres, and a higher proportion of immature naive T cells and regulatory T cells (Tregs). Furthermore, the phenomenon of maternal microchimerism plays a pivotal role in long-term immune tolerance, allowing UCB to be well-tolerated even in cases of significant HLA mismatch.
Despite a global inventory of over 800,000 units in public banks, the utilization of CBT has faced challenges in recent years. Data indicates a decline in CBT frequency, largely driven by the rise of haploidentical transplantation (Haplo-HCT) utilizing post-transplant cyclophosphamide (PTCy). In Europe and the United States, CBT currently accounts for approximately 4% of all allogeneic transplants. Prof. Ruggeri identified delayed engraftment as the primary limitation hindering the broader adoption of CBT.
02 Critical Factors for Optimizing Outcomes: Cell Dose and ATG Utilization
To improve the efficacy of CBT, Prof. Ruggeri proposed two key technical interventions:
- Cell Dose Thresholds: Early studies confirmed that a Total Nucleated Cell (TNC) dose exceeding 2.5–3.0 × 10^7/kg is essential for improving prognosis. Similarly, the CD34+ cell dose is a decisive factor in engraftment speed.
- The Role of Anti-Thymocyte Globulin (ATG): In CBT, ATG has traditionally been included in conditioning regimens to prevent graft-versus-host disease (GVHD) due to high HLA mismatch. However, data from several institutions (e.g., University of Rotterdam) demonstrate that ATG significantly impairs immune reconstitution, particularly of CD4+ T cells. Conversely, ATG-free conditioning regimens allow for the rapid recovery of CD4+ T cells within one month post-transplant, facilitating a robust anti-infection response and the graft-versus-leukemia (GVL) effect.
03 GVL Effect and HLA Loss: The Advantage of CBT in MRD Clearance
Regarding disease control, CBT demonstrates a potent GVL effect. Research groups in Seattle and Manchester have shown that for high-risk leukemia patients who are minimal residual disease (MRD) positive prior to transplant, the risk of relapse after CBT is significantly lower compared to haploidentical or matched unrelated donor transplants.
Prof. Ruggeri highlighted the mechanism of HLA loss of heterozygosity (HLA LOH) in relapsed disease. In haploidentical transplants, approximately 30% of relapses are associated with the downregulation or loss of donor-specific HLA haplotypes by tumor cells. However, collaborative research by Prof. Luca Vago and Prof. Ruggeri’s team revealed that HLA loss is extremely rare in the CBT setting (only 2 out of 75 relapses, approx. 2.6%). Because CBT mismatches typically involve both haplotypes, it is much more difficult for tumor cells to achieve immune escape via a single genomic loss, establishing CBT as a superior platform for relapse prevention.
04 Ex Vivo Expansion Technologies: Breakthroughs from Omidubicel to UM171
To fundamentally address the issue of insufficient UCB cell quantity, ex vivo expansion technologies have entered the clinical translation phase:
- Omidubicel: Approved by the US FDA in April 2023 for patients with hematologic malignancies. While clinical data showed significant reductions in engraftment time, its widespread adoption has been hindered by manufacturing costs and commercial supply issues.
- UM171 (MTE-2) Expansion Technology: Developed by Guy Sauvageau’s team in Montreal, UM171 facilitates the massive expansion of CD34+ cells while maintaining or even enhancing T-cell receptor (TCR) diversity and NK-cell recovery.
- Clinical Benefits: In Phase 1/2 trials focusing on high-risk malignancies, single CBT using UM171-expanded grafts demonstrated exceptionally low NRM and superior progression-free survival (PFS) compared to historical EBMT registry cohorts (including 10/10 MUD, 9/10 MUD, and Haplo). Furthermore, patients experienced significantly shorter hospital stays and more rapid immune reconstitution.
Conclusion and Outlook
Professor Annalisa Ruggeri concluded that cord blood transplantation is currently at a tipping point, shifting from a “traditional” to a “regenerative” model. Through precise TNC/CD34+ dose selection, the omission of ATG in conditioning, and the introduction of highly efficient expansion technologies like UM171, CBT is now capable of achieving engraftment speeds and survival benefits comparable to, or even exceeding, peripheral blood or bone marrow sources. Looking forward, umbilical cord blood remains a promising platform for cellular therapies (such as NK-cell therapy and gene therapy), and CBT continues to be a vital therapeutic option for high-risk, particularly MRD-positive, patients.
